These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 15077157)

  • 1. Prospective strategies to enforce selectively cell death in cancer cells.
    Blagosklonny MV
    Oncogene; 2004 Apr; 23(16):2967-75. PubMed ID: 15077157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apoptosis signaling in tumor therapy.
    Fulda S; Debatin KM
    Ann N Y Acad Sci; 2004 Dec; 1028():150-6. PubMed ID: 15650241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of the resistance to TRAIL-induced apoptosis as a new strategy for pancreatic cancer.
    Mori T; Doi R; Toyoda E; Koizumi M; Ito D; Kami K; Kida A; Masui T; Kawaguchi Y; Fujimoto K
    Surgery; 2005 Jul; 138(1):71-7. PubMed ID: 16003319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bypassing cancer drug resistance by activating multiple death pathways--a proposal from the study of circumventing cancer drug resistance by induction of necroptosis.
    Hu X; Xuan Y
    Cancer Lett; 2008 Feb; 259(2):127-37. PubMed ID: 18082322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting death-inducing receptors in cancer therapy.
    Takeda K; Stagg J; Yagita H; Okumura K; Smyth MJ
    Oncogene; 2007 May; 26(25):3745-57. PubMed ID: 17530027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications.
    Shankar S; Srivastava RK
    Drug Resist Updat; 2004 Apr; 7(2):139-56. PubMed ID: 15158769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TRAIL and malignant glioma.
    Hawkins CJ
    Vitam Horm; 2004; 67():427-52. PubMed ID: 15110189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploiting cancer cell cycling for selective protection of normal cells.
    Blagosklonny MV; Pardee AB
    Cancer Res; 2001 Jun; 61(11):4301-5. PubMed ID: 11389048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticancer therapeutics: "Addictive" targets, multi-targeted drugs, new drug combinations.
    Broxterman HJ; Georgopapadakou NH
    Drug Resist Updat; 2005 Aug; 8(4):183-97. PubMed ID: 16154800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting senescence pathways to reverse drug resistance in cancer.
    Rebbaa A
    Cancer Lett; 2005 Feb; 219(1):1-13. PubMed ID: 15694659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitor of apoptosis proteins as targets for anticancer therapy.
    Fulda S
    Expert Rev Anticancer Ther; 2007 Sep; 7(9):1255-64. PubMed ID: 17892425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting hypoxia cell signaling for cancer therapy.
    Melillo G
    Cancer Metastasis Rev; 2007 Jun; 26(2):341-52. PubMed ID: 17415529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of reactive oxygen species renders mutant and wild-type K-ras pancreatic carcinoma cells susceptible to Ad.mda-7-induced apoptosis.
    Lebedeva IV; Su ZZ; Sarkar D; Gopalkrishnan RV; Waxman S; Yacoub A; Dent P; Fisher PB
    Oncogene; 2005 Jan; 24(4):585-96. PubMed ID: 15580305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(waf1).
    Chopin V; Slomianny C; Hondermarck H; Le Bourhis X
    Exp Cell Res; 2004 Aug; 298(2):560-73. PubMed ID: 15265702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autophagy signaling in cancer and its potential as novel target to improve anticancer therapy.
    Moretti L; Yang ES; Kim KW; Lu B
    Drug Resist Updat; 2007; 10(4-5):135-43. PubMed ID: 17627865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Signaling through death receptors in cancer therapy.
    Fulda S; Debatin KM
    Curr Opin Pharmacol; 2004 Aug; 4(4):327-32. PubMed ID: 15251124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5.
    Zhang Y; Zhang B
    Mol Cancer Res; 2008 Dec; 6(12):1861-71. PubMed ID: 19074831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5.
    Park SJ; Wu CH; Choi MR; Najafi F; Emami A; Safa AR
    Biochem Pharmacol; 2006 Jul; 72(3):293-307. PubMed ID: 16753135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell death in response to antimetabolites directed at thymidylate synthase.
    Barbour KW; Berger FG
    Cancer Chemother Pharmacol; 2008 Feb; 61(2):189-201. PubMed ID: 17396263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combinatorial action of the HDAC inhibitor trichostatin A and etoposide induces caspase-mediated AIF-dependent apoptotic cell death in non-small cell lung carcinoma cells.
    Hajji N; Wallenborg K; Vlachos P; Nyman U; Hermanson O; Joseph B
    Oncogene; 2008 May; 27(22):3134-44. PubMed ID: 18071312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.